Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-000809-23
    Sponsor's Protocol Code Number:AB12003
    National Competent Authority:Slovakia - SIDC (Slovak)
    Clinical Trial Type:EEA CTA
    Trial Status:Prohibited by CA
    Date on which this record was first entered in the EudraCT database:2014-04-29
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSlovakia - SIDC (Slovak)
    A.2EudraCT number2013-000809-23
    A.3Full title of the trial
    A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC)
    Prospektívna, multicentrická, randomizovaná, dvojito zaslepená, placebom kontrolovaná, s dvomi paralelnými skupinami, štúdia fázy III na porovnanie účinnosti a bezpečnosti masitinibu v kombinácii s docetaxelom oproti placebu v kombinácii s docetaxelom v prvej línii metastatického kastračne rezistentného karcinómu prostaty (mCRPC)
    ŠTÚDIA: AB12003
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to evaluate 2 types of treatment as first line treatment (masitinib + docetaxel or placebo + docetaxel ) in the treatment of patients with metastatic Castrate Resistant Prostate Cancer (mCRPC)
    Štúdia na zhodnotenie 2 typov liečby ako prvej línie liečby (masitinib + docetaxel alebo placebo + docetaxel) pri liečbe pacientov s metastatickou kastračne rezistentnou rakovinou prostaty (mCRPC)
    A.4.1Sponsor's protocol code numberAB12003
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAB Science
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAB Science
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAB Science
    B.5.2Functional name of contact pointAlain Moussy
    B.5.3 Address:
    B.5.3.1Street Address3 avenue George V
    B.5.3.2Town/ cityPARIS
    B.5.3.3Post code75008
    B.5.3.4CountryFrance
    B.5.4Telephone number+331 40 70 14 99
    B.5.5Fax number+331 47 20 24 11
    B.5.6E-mailalain.moussy@ab-science.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namemasitinib 100mg
    D.3.2Product code AB1010
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMasitinib Mesylate
    D.3.9.1CAS number 790299-79-5
    D.3.9.2Current sponsor codeAB1010
    D.3.9.3Other descriptive nameMASITINIB
    D.3.9.4EV Substance CodeSUB32266
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namemasitinib 200mg
    D.3.2Product code AB1010
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMasitinib Mesylate
    D.3.9.1CAS number 790299-79-5
    D.3.9.2Current sponsor codeAB1010
    D.3.9.3Other descriptive nameMASITINIB
    D.3.9.4EV Substance CodeSUB32266
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    metastatic Castrate Resistant Prostate Cancer (mCRPC).
    metastatický kastračne rezistentný karcinóm prostaty (mCRPC).
    E.1.1.1Medical condition in easily understood language
    metastatic Castrate Resistant Prostate Cancer (mCRPC).
    metastatický kastračne rezistentný karcinóm prostaty (mCRPC).
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Overall survival (OS)
    Celkové prežitie (OS)
    E.2.2Secondary objectives of the trial
    Secondary endpoint
    • Survival rate every 6 months
    • Overall Progression Free Survival (PFS)
    • PFS rate every 12 weeks
    • Overall Time To Progression (TTP)
    • TTP rate every 12 weeks
    • Best response rate, Objective Response rate: Complete Response (CR) or Partial Response (PR) and disease control rate (CR+ PR+ SD) every 12 weeks
    • Decline of PSA level ≥ 30% from baseline at time point
    • Quality of life assessment every 6 weeks Quality of Life according to the EORTC QLQ-C30 questionnaire
    • Miera prežitia každých 6 mesiacov
    • Celková miera prežitia bez progresie (TTP)
    • miera TTP každých 12 týždňov
    • Najlepšia miera odozvy, objektívna miera odozvy: úplná odozva (CR) alebo čiastočná odpoveď (PR) a miera kontroly ochorenia (CR+PR+SD) každých 12 týždňov
    • Pokles PSA hladiny ≥ 30% od baseline v časovom bode
    • hodnotenie kvality života každých 6 týždňov Kvalita života podľa dotazníku EORTC QLQ-C30
    o Súčasné skóre intenzity bolesti založené na McGill-Melzackovom dotazníku bolesti (MPQ)
    o užívanie analgetík
    o ECOG výkonnostný stav
    o zlepšenie bolesti (VAS)
    • Farmakogenomické hodnotenie: vzťah medzi genomickými dátami a celkovým prežitím.
    • Bezpečnostný profil za použitia klasifikácie NCI CTC v4.03
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    pharmacogenomic study: Relationship between genomic data and overall survival
    farmakogenomická štúdia: Vzťah medzi genomickými dátami a celkovým prežitím
    E.3Principal inclusion criteria
    1. 1. Patient aged ≥ 18 years old, with histologically or cytologically confirmed metastatic Castrate Resistant Prostate Cancer (medical or surgical castration: androgens deprivation by GnHR agonist or antagonist or patient with surgical castration; hormonal castration confirmed biologically (testosterone < 0.5ng/ml) with one of the following criteria:
    - Pre-treated with abiraterone with progressed disease documented, OR
    - with indication for initiating docetaxel administration (e.g., widespread visceral disease or rapidly progressive disease).

    2. Patient with evidence of progressive metastatic disease. Disease progression at trial enrolment is based on progression in at least one variable described in Table 5.
    3. Patient with ECOG ≤ 1
    4. Patient with adequate organ function:
    • Absolute neutrophil count (ANC) ≥ 1.5 x 10ç/L
    • Haemoglobin ≥ 10 g/dL
    • Platelets (PTL) ≥ 75 x 109/L
    • AST/ALT ≤ 3x ULN (≤5 x ULN in case of liver metastases)
    • Gamma GT ≤2.5 x ULN (≤5 x ULN in case of liver metastases)
    • Bilirubin ≤ 1.5x ULN
    • Normal creatinine or if abnormal creatinine, creatinine clearance ≥ 50 mL/min (Cockcroft and Gault formula)
    • Albumin > 1 x LLN
    • Proteinuria < 30 mg/dL (1+) on the dipstick; in case of proteinuria ≥ 1+ on the dipstick, 24 hours proteinuria must be ≤ 1.5g/24h
    5. Patient with life expectancy > 6 months
    6. Patient with BMI > 18 and patient weight > 40 kg
    7. Male patients must use medically acceptable methods of contraception if your female partner is pregnant, from the time of the first administration of the study drug until three months following administration of the last dose of study drug. Acceptable methods include:
    • Condom;
    • If you have undergone surgical sterilization (vasectomy with documentation of azoospermia) a condom should also be used.
    Male patients must use two highly effective methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake. The acceptable methods of contraception are as follows:
    • Condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository;
    • Surgical sterilization (vasectomy with documentation of azoospermia) and a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps] used with spermicidal foam/gel/film/cream/suppository);
    • Your female partner uses oral contraceptives (combination oestrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps] used with spermicidal foam/gel/film/cream/suppository);
    • Medically prescribed topically-applied transdermal contraceptive patch and a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps] used with spermicidal foam/gel/film/cream/suppository);
    • Your female partner has undergone documented tubal ligation (female sterilization). In addition, a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps] used with spermicidal foam/gel/film/cream/suppository) should also be used;
    • Your female partner has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS) and the use of a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps] used with spermicidal foam/gel/film/cream/suppository);
    • Abstinence.

    8. Patient able and willing to comply with study procedures as per protocol
    9. Patient able to understand, sign, and date the written informed consent form at the screening visit prior to any protocol-specific procedures are performed. If the patient is deemed by the treating physician to be cognitively impaired or questionably impaired in such a way that the ability of the patient to give informed consent is questionable, the designated legal guardian must sign the informed consent.
    10. Patient able to understand the patient card and to follow the patient card procedures in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity, during the first 2 months of treatment.
    1. Pacient vo veku ≥ 18 rokov, s histologicky alebo cytologicky potvrdeným metastatickým kastračne rezistentným karcinómom prostaty (chemická alebo chirurgická kastrácia: odstránenie androgénov pomocou GnHR agonistu alebo antagonistu alebo pacient s chirurgickou kastráciou; hormonálnou kastráciou potvrdenou biologicky (testosterón < 0,5 ng/ml) s jedným z nasledujúcich kritérií:
    - Predchádzajúca liečba s abiteraterone so zdokumentovanou progresiou choroby ALEBO
    - s indikáciou pre začatie podávania docetaxelu (napr. rozšírená viscerálna choroba alebo choroba s rýchlou progresiou).
    2. Pacient s evidenciou postupujúceho metastatického ochorenia. Progresia ochorenia pri nábere štúdie je založené na postupe aspoň jednej premennej popísanej v tabuľke 5.
    3. Pacient s ECOG ≤ 1
    4. Pacient s dostatočnou orgánovou funkciou:
    • absolútny počet neutrofilov (ANC) ≥ 1.5 x 109/L
    • Hemoglobín ≥ 10 g/dL
    • Krvné doštičky (PTL) ≥ 75 x 109/L
    • AST / ALT ≤ 3x ULN (≤ 5 x ULN v prípade metastáz pečene)
    • Gamma GT ≤ 2.5x ULN (≤ 5 x ULN v prípade metastáz pečene)
    • Bilirubín ≤ 1.5x ULN
    • Normálny kreatinín alebo pokiaľ abnormálny kreatinín, klírens kreatinínu ≥ 50 mL/min (Cockroftov a Gaultov vzorec)
    • Albumín ˃ 1 x LLN
    • Proteinúria < 30 mg/dL (1+) na dipsticku; v prípade proteinúrie ≥ 1+ na dipsticku, 24 hodinová proteinúria musí byť ≤ 1.5g/24h
    5. Pacient s očakávanou dĺžkou života ˃ 6 mesiacov
    6. Pacient s BMI ˃ 18 a pacientova váha ˃ 40 kg
    7. Mužskí pacienti musia používať lekársky prijateľné formy antikoncepcie, pokiaľ je ich partnerka tehotná, alebo od doby prvého podania hodnoteného prípravku až do troch mesiacov po poslednej dávke skúšaného lieku. Prijateľné formy sú:
    • kondóm
    • chirurgická sterilizácia (vasektómia so zdokumentovanou azoospermiou) , je treba používať aj kondóm
    Mužskí pacienti musia počas štúdie a 3 mesiace po poslednej liečbe používať dve metódy lekársky prijateľnej vysoko účinnej antikoncepcie (jednu pacient a druhú partnerka). Prijateľné formy antikoncepcie sú:
    • kondóm alebo pesar (diafragma alebo cervikálny klobúčik) v kombinácii so spermicídnou penou/gélom/krémom/čiapikmi.
    • chirurgická sterilizácia (vasektómia so zdokumentovanou azoospermiou) a bariérový spôsob ochrany (kondóm alebo pesar [diafragma alebo cervikálny klobúčik] v kombinácii so spermicídnou penou/gélom/krémom/čiapikmi).
    • Vaša partnerka používa perorálnu antikoncepciu (kombinované tablety s estrogénom či progesterónom), injekcie progesterónu či podkožné implantáty a bariérový spôsob ochrany (kondóm alebo pesar [diafragma alebo cervikálny klobúčik] v kombinácii so spermicídnou penou/gélom/krémom/čiapikmi).
    • lekárom predpísaná antikoncepčná náplasť a bariérová metóda (kondóm alebo pesar [diafragma alebo cervikálny klobúčik] v kombinácii so spermicídnou penou/gélom/krémom/číapikmi).
    • Vaša partnerka podstúpila zdokumentované zavedenie vnútromaternicového telieska (IUD) alebo vnútromaternicového systému (IUS) či použitie bariérového spôsobu ochrany ((kondóm alebo pesar [diafragma alebo cervikálny klobúčik] v kombinácii so spermicídnou penou/gélom/krémom/čiapikmi).
    • abstinencia
    8. Pacient schopný a ochotný postupovať podľa postupov uvedených v protokole
    9. Pacienti, ktorí rozumejú, podpíšu a datujú písomný informovaný súhlas pri screenovacej návšteve pred zahájením akýchkoľvek procedúr daných protokolom. Pokiaľ ošetrujúci lekár zistí u pacienta oslabenú alebo spornú kogníciu v takej miere, že schopnosť pacienta dať informovaný súhlas je neistá, tento súhlas musí podpísať stanovený zákonný zástupca.
    10. Pacienti schopní porozumieť kartičke pacienta a riadiť sa postupmi v nej, v prípade príznakov alebo symptómov ťažkej neutropénie alebo ťažkej kožnej toxicity počas prvých 2 mesiacov liečby.
    E.4Principal exclusion criteria
    1. Patient who has been previously treated with chemotherapy.
    2. Patient with bone marrow irradiation > 40% within 12 months before baseline
    3. Patient treated for a cancer other than prostate cancer within 3 years before enrollment, with the exception of basal cell carcinoma (and pTa or pT1)
    4. Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
    5. Patient presenting with cardiac disorders defined by at least one of the following conditions:
    • Patient with recent cardiac history (within 6 months) of:
    o Acute coronary syndrome
    o Acute heart failure (class III or IV of the NYHA classification)
    o Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
    • Patient with cardiac failure class III or IV of the NYHA classification
    • Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
    • Syncope without known aetiology within 3 months
    • Uncontrolled severe hypertension, according to the judgement of the investigator, or symptomatic hypertension
    1. Pacient, ktorý bol v minulosti liečený s chemoterapiou
    2. Pacient s ožarovaním kostnej drene ˃ 40% počas 10 mesiacov pred baseline
    3. Pacient liečený na rakovinu inú než rakovinu prostaty počas 3 rokov pred zaradením, s výnimkou karcinómu bazálnych buniek (a pTa alebo aT1).
    4. Pacienti s aktívnou metastázou centrálneho nervového systému (CNS) alebo s anamnézou metastáz CNS.
    5. Pacienti s ochorením srdca spĺňajúcim aspoň jednu z nasledujúcich podmienok:
    • Pacienti, ktorým boli v posledných 6 mesiacoch zistené tieto ochorenia srdca:
    o Akútny koronárny syndróm
    o Akútne srdečné zlyhanie (trieda III alebo IV podľa klasifikácie NYHA)
    o Výrazná srdečná arytmia (pretrvávajúca komorová tachykardia, fibrilácia komôr, resuscitovaná náhla srdečná smrť).
    • Pacienti so srdečným zlyhaním triedy III alebo IV podľa klasifikácie NYHA.
    • Pacienti so závažnými poruchami vedenia vzruchu, ktoré nie sú upravené trvalou kardiostimuláciou (atrioventrikulárna blokáda II. a III. stupňa, sinoatriálna blokáda).
    • Synkópa bez známej etiológie v posledných 3 mesiacoch.
    • Nekontrolovaná ťažká hypertenzia podľa posudku skúšajúceho, alebo symptomatická hypertenzia
    6. Pacienti s anamnézou nedôsledného dodržiavania liečby alebo s anamnézou užívania narkotík či alkoholu, alebo nadmerného užívania alkoholu, ktoré by mohlo narušiť dodržovanie protokolu štúdie, alebo pretrvávajúce či prekonané psychiatrické ochorenie, ktoré by mohlo narušiť dodržiavanie protokolu alebo poskytnutie informovaného súhlasu.
    7. Pacient liečený akoukoľvek proti nádorovou liečbou (akákoľvek rádioterapia, chemoterapia, biologická alebo anti-androgénna liečba s výnimkou GnRH/LHRH analógov)
    E.5 End points
    E.5.1Primary end point(s)
    • Overall Survival (OS) is defined as the time from the randomization to the date of documented death
    • Celkové prežitie (OS) je definované ako čas od randomizácie do dátumu zdokumentovanej smrti
    E.5.1.1Timepoint(s) of evaluation of this end point
    Date of documented death
    Dátum zdokumentovanej smrti
    E.5.2Secondary end point(s)
    • Survival rate every 6 months
    • Overall Progression Free Survival (PFS)
    • PFS rate every 12 weeks
    • Overall Time To Progression (TTP)
    • TTP rate every 12 weeks
    • Miera prežitia každých 6 mesiacov
    • Celkové prežitie bez progresie (PFS)
    • Miera PFS každých 12 týždňov
    • Celkový čas do progresie (TTP)
    • Miera TTP každých 12 týždňov
    E.5.2.1Timepoint(s) of evaluation of this end point
    Every 12 weeks
    Každých 12 týždňov
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA50
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Austria
    Belgium
    Brazil
    Canada
    China
    Czech Republic
    Greece
    Hong Kong
    Hungary
    India
    Italy
    Korea, Republic of
    Malaysia
    Mexico
    Morocco
    Peru
    Philippines
    Poland
    Romania
    Russian Federation
    Singapore
    South Africa
    Spain
    Tunisia
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    patient treated until disease progression limiting toxicity or consent withdrawal. Follow-up performed until patient's death
    Pacient bude liečený do progresie, limitujúcej toxicity alebo odvolania súhlasu. Obdobie následného sledovania bude prebiehať do pacientovho úmrtia
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 250
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 300
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 200
    F.4.2.2In the whole clinical trial 581
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-08-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-05-14
    P. End of Trial
    P.End of Trial StatusProhibited by CA
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 20:50:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA